Medical/Pharmaceuticals
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...
PanBrain Tech Unveils Breakthrough Brain-Computer Interface Device at BEYOND EXPO 2025 in Macau
MACAU, June 23, 2025 /PRNewswire/ -- Brain science technology company PanBrain
Tech Co., Ltd.
OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer
PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced the appointment ofDimitry S.A. Nuyten, M.D.,...
IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an ...
Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collabora...
Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for...
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
* Maintained Quarterly Operational Profitability * Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY * Maintained Quarterly Positive Operating Cash Flow SHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled h...
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative
oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today
announced the first US patient has started treatment in the ongoing Phase 1
trial (SIM0500-101,NCT06375044
MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®
TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI
Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer
Strategic appointments reflect Medison's continued investment in global scale
and operational excellence
PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison
Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program
PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-yea...
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI, June 17, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near...
AI-Powered CDSS Enhances Patient Safety with Real-World Data
SAN FRANCISCO, June 17, 2025 /PRNewswire/ -- The growing demand for
personalized medicine has accelerated the adoption of Real-World Data (RWD) in
healthcare.The Tungs' Taichung MetroHarbor Hospital
Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Highlights * Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for64Cu-SAR-bisPSMA. * SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and64Cu-SAR-bisPSMA under one roof and enables distribution to all 50 sta...
HanchorBio Presents Promising Data on HCB101 Checkpoint Inhibitor Immunotherapy at ASCO
Interim data on the cancer treatment shows robust potential for balancing
efficacy and safety
TAIPEI and SHANGHAI and SAN FRANCISCO, June 17, 2025 /PRNewswire/ --
Following a successful launch of Phase 2 clinical trials in March, HanchorBio
VSA Signs Letter of Intent to Acquire HopeAI, Accelerating Expansion into AI in Life Science
BEIJING, June 17, 2025 /PRNewswire/ -- TCTM Kids IT Education Inc. (Nasdaq: VSA) (the "Company" or "VSA") today announced that it has entered into a non-binding letter of intent ("LOI") to acquire HopeAI Inc. ("HopeAI"), a leading artificial intelligence company specializing in AI-powered clinica...
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022
(RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage --
SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
CodeSteri Launches PlaDeo: The World's First Bio-Plasma Powered Deodorant Device
A Breakthrough in Underarm Odor Control and Axillary Bromhidrosis Treatment SEOUL, South Korea, June 16, 2025 /PRNewswire/ -- CodeSteri Inc., a tech-driven startup based at theHanyang University College of Medicine in Seoul , today announced the launch ofPlaDeo, the world's first electronic deodor...
HELP Therapeutics and China Resources Sanjiu Announce Strategic Partnership to Co-Develop and Commercialize HiCM-188 for Advanced Heart Failure in Mainland China
NANJING, China, June 16, 2025 /PRNewswire/ -- HELP Therapeutics, a global leader in regenerative medicine, and China Resources Sanjiu Pharmaceutical Company, one ofChina's largest pharmaceutical companies, have announced a strategic partnership to co-develop and commercialize the investigational ...
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
* Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma * Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 * Partnership leverages stra...
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09